Important determinants of bone strength: Beyond bone mineral density

Journal of Clinical Rheumatology

Volumn 12, Issue 2, 2006, Pages 70-77

  Friedman, Alan W ^a  

^a Medical Clinic of Houston   (United States)

Author keywords

Bone mineral density; Bone turnover; Microarchitecture; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN; ESTRADIOL; FLUORIDE; GLUCOCORTICOID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; SALCATONIN;

ARTICLE; BONE DENSITY; BONE DISEASE; BONE FRAGILITY; BONE MINERAL; BONE MINERALIZATION; BONE STRENGTH; BONE TURNOVER; CROSS LINKING; CRYSTAL STRUCTURE; DIAGNOSTIC TEST; DISEASE MARKER; DISEASE PREDISPOSITION; FRACTURE; HUMAN; IMAGING SYSTEM; OSTEOPOROSIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TREATMENT RESPONSE; VERTEBRA FRACTURE;

AGING; BONE AND BONES; BONE DENSITY; CALCIFICATION, PHYSIOLOGIC; COLLAGEN; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; STRESS;

EID: 33748145960     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1353/psg.2006.0122     Document Type: Article

References (108)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785-795.
2. Beck T. Measuring the structural strength of bones with dual-energy x-ray absorptiometry: principles, technical limitations, and future possibilities. Osteoporos Int. 2003;14(suppl 5):81-88.
3. Einhorn TA. Bone strength: the bottom line. Calcif Tissue Int. 1992;51:333-339.
4. Turner CH. Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int. 2002;13:97-104.
5. Ahlborg HG, Johnell O, Nilsson BE, et al. Bone loss in relation to menopause: a prospective study during 16 years. Bone. 2001;28:327-331.
6. Pouilles JM, Tremollieres F, Ribot C. Effect of menopause on femoral and vertebral bone loss. J Bone Miner Res. 1995;10:1531-1536.
7. Riggs BL, Khosla S, Melton LJ 3rd. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res. 1998;13:763-773.
8. American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis American College of Rheumatology Task Force on Osteoporosis Guidelines. Arthritis Rheum. 1996;39:1791-1801.
9. LoCascio V, Bonucci E, Imbimbo B, et al. Bone loss in response to long-term glucocorticoid therapy. Bone Miner. 1990;8:39-51.
10. Laan RF, van Riel PL, van de Putte LB, et al. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med. 1993;119:963-968.
11. Reid IR, Evans MC, Wattie DJ, et al. Bone mineral density of the proximal femur and lumbar spine in glucocorticoid-treated asthmatic patients. Osteoporos Int. 1992;2:103-105.
12. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 1999;42:2309-2318.
13. Haugeberg G, Uhlig T, Falch JA, et al. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum. 2000;43:522-530.
14. Perez-Edo L, Diez-Perez A, Marinoso L, et al. Bone metabolism and histomorphometric changes in rheumatoid arthritis. Scand J Rheumatol. 2002;31:285-290.
15. Chesnut CH 3rd, Rose CJ. Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture. J Bone Miner Res. 2001;16:2163-2172.
16. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1-129.
17. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:1254-1259.
18. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. JAMA. 2002;288:1889-1897.
19. National Osteoporosis Foundation. Physician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2003.
20. Wainwright S, Phipps K, Stone J, et al. A large proportion of fractures in postmenopausal women occur with baseline bone mineral density T-score -2.5. J Bone Miner Res. 2001;16:S155.
21. Dargent-Molina P, Piault S, Breart G. A comparison of different screening strategies to identify elderly women at high risk of hip fracture: results from the EPIDOS prospective study. Osteoporos Int. 2003;14:969-977.
22. Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004;164:1108-1112.
23. Schuit SC, van der Klift M, Weel AE, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone. 2004;34:195-202.
24. Kanis JA, Johnell O, Oden A, et al. The risk and burden of vertebral fractures in Sweden. Osteoporos Int. 2004;15:20-26.
25. Van Staa TP, Laan RF, Barton IP, et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003;48:3224-3229.
26. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002;112:281-289.
27. Sarkar S, Mitlak BH, Wong M, et al. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res. 2002;17:1-10.
28. Watts NB, Cooper C, Lindsay R, et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom. 2004;7:255-261.
29. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282:637-645.
30. Chesnut CH 3rd, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000;109:267-276.
31. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA. 1999;282:1344-1352.
32. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000;11:83-91.
33. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535-1541.
34. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077-2082.
35. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-1441.
36. Meunier PJ, Sebert JL, Reginster JY, et al. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVO Study. Osteoporos Int. 1998;8:4-12.
37. Blake GM, Fogelman I. The role of bone density measurements in the evaluation of new treatments for osteoporosis. Curr Pharm Des. 2002;8:1885-1905.
38. Watts NB. Bone quality: getting closer to a definition. J Bone Miner Res. 2002;17:1148-1150.
39. Roux C, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within 6 months. Curr Med Res Opin. 2004;20:433-439.
40. Harrington JT, Ste.-Marie LG, Brandi ML, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int. 2004;74:129-135.
41. Mundy GR, Chen D, Babatunde OO. Bone remodeling. In: Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2003:46-58.
42. Forsmo S, Langhammer A, Forsen L, et al. Forearm bone mineral density in an unselected population of 2,779 men and women - the HUNT Study, Norway. Osteoporos Int. 2005;16:562-567.
43. Riggs BL, Melton LJ 3rd, O'Fallon WM. Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone. 1996;18(suppl):197S-201S.
44. Silva MJ, Gibson LJ. Modeling the mechanical behavior of vertebral trabecular bone: effects of age-related changes in microstructure. Bone. 1997;21:191-199.
45. Parfitt AM, Mathews CH, Villanueva AR, et al. Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss. J Clin Invest. 1983;72:1396-1409.
46. Seeman E. Pathogenesis of bone fragility in women and men. Lancet. 2002;359:1841-1850.
47. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest. 1996;97:2692-2696.
48. Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int. 2002;71:103-111.
49. Schnitzer T, Bone H, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano). 2000;12:1-12.
50. Lindsay R, Gallagher JC, Kleerekoper M, et al. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA. 2002;287:2668-2676.
51. Eastell R, Barton I, Hannon RA, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003;18:1051-1056.
52. Sarkar S, Reginster JY, Crans GG, et al. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res. 2004;19:394-401.
53. Hammett-Stabler CA. The use of biochemical markers in osteoporosis. Clin Lab Med. 2004;24:175-197.
54. Guo XE, Kim CH. Mechanical consequence of trabecular bone loss and its treatment: a three-dimensional model simulation. Bone. 2002;30:404-411.
55. Bell GH, Dunbar O, Beck JS, et al. Variations in strength of vertebrae with age and their relation to osteoporosis. Calcif Tissue Res. 1967;1:75-86.
56. Legrand E, Chappard D, Pascaretti C, et al. Trabecular bone microarchitecture, bone mineral density, and vertebral fractures in male osteoporosis. J Bone Miner Res. 2000;15:13-19.
57. Oleksik A, Ott SM, Vedi S, et al. Bone structure in patients with low bone mineral density with or without vertebral fractures. J Bone Miner Res. 2000;15:1368-1375.
58. Dalle Carbonare L, Arlot ME, Chavassieux PM, et al. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res. 2001;16:97-103.
59. Chappard D, Legrand E, Basle MF, et al. Altered trabecular architecture induced by corticosteroids: a bone histomorphometric study. J Bone Miner Res. 1996;11:676-685.
60. Weinstein RS, Manolagas SC. Apoptosis and osteoporosis. Am J Med. 2000;108:153-164.
61. Luengo M, Picado C, Del Rio L, et al. Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study. Thorax. 1991;46:803-806.
62. Dufresne TE, Chmielewski PA, Manhart MD, et al. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcif Tissue Int. 2003;73:423-432.
63. Borah B, Dufresne TE, Chmielewski PA, et al. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone. 2004;34:736-746.
64. Dempster DW, Cosman F, Kurland ES, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res. 2001;16:1846-1853.
65. Zanchetta JR, Bogado CE, Ferretti JL, et al. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res. 2003;18:539-543.
66. Bouxsein ML. Bone quality: where do we go from here? Osteoporos Int. 2003;14(suppl 5):118-127.
67. Beck T. Measuring the structural strength of bones with dual-energy x-ray absorptiometry: principles, technical limitations, and future possibilities. Osteoporos Int. 2003;14(suppl 5):81-88.
68. Jacobs-Kosmin D, Sandorfi N, Murray H, et al. Vertebral deformities identified by vertebral fracture assessment: associations with clinical characteristics and bone mineral density. J Clin Densitom. 2005;8:267-272.
69. Duboeuf F, Bauer DC, Chapurlat RD, et al. Assessment of vertebral fracture using densitometric morphometry. J Clin Densitom. 2005;8:362-368.
70. Link TM, Majumdar S. Current diagnostic techniques in the evaluation of bone architecture. Curr Osteoporos Rep. 2004;2:47-52.
71. Sell CA, Masi JN, Burghardt A, et al. Quantification of trabecular bone structure using magnetic resonance imaging at 3 Tesla - calibration studies using microcomputed tomography as a standard of reference. Calcif Tissue Int. 2005;76:355-364.
72. Chesnut CH 3rd, Majumdar S, Newitt DC, et al. Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study. J Bone Miner Res. 2005;20:1548-1561.
73. Albrand G, Munoz F, Sornay-Rendu E, et al. Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: the OFELY study. Bone. 2003;32:78-85.
74. Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004;35:375-382.
75. Siris ES, Miller PD, Barrett-Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA. 2001;286:2815-2822.
76. Taylor BC, Schreiner PJ, Stone KL, et al. Long-term prediction of incident hip fracture risk in elderly white women: study of osteoporotic fractures. J Am Geriatr Soc. 2004;52:1479-1486.
77. Kanis JA, Johnell O, Oden A, et al. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int. 2001;12:989-995.
78. Woolf AD, Akesson K. Preventing fractures in elderly people. BMJ. 2003;327:89-95.
79. Tinetti ME. Clinical practice. Preventing falls in elderly persons. N Engl J Med. 2003;348:42-49.
80. American Geriatrics Society, British Geriatrics Society, Prevention AAoOSPoF. Guideline for the prevention of falls in older persons. J Am Geriatr Soc. 2001;49:664-672.
81. Grisso JA, Kelsey JL, Strom BL, et al. Risk factors for falls as a cause of hip fracture in women. The Northeast Hip Fracture Study Group. N Engl J Med. 1991;324:1326-1331.
82. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med. 1995;332:767-773.
83. Seeman E. Clinical review 137: sexual dimorphism in skeletal size, density, and strength. J Clin Endocrinol Metab. 2001;86:4576-4584.
84. Bono CM, Einhorn TA. Overview of osteoporosis: pathophysiology and determinants of bone strength. Eur Spine J. 2003;12(suppl 2):S90-96.
85. Turner CH, Burr DB. Basic biomechanical measurements of bone: a tutorial. Bone. 1993;14:595-608.
86. Ammann P, Rizzoli R, Meyer JM, et al. Bone density and shape as determinants of bone strength in IGF-I and/or pamidronate-treated ovariectomized rats. Osteoporos Int. 1996;6:219-227.
87. El-Kaissi S, Pasco JA, Henry MJ, et al. Femoral neck geometry and hip fracture risk: the Geelong osteoporosis study. Osteoporos Int. 2005;16:1299-1303.
88. Frisoli A Jr, Szejnfeld VL, Delmonte Piovezan R, et al. Hip axis length as an independent risk factor for hip fracture independently of femoral bone mineral density in Caucasian elderly Brazilian women. Bone. 2005.
89. Nelson DA, Barondess DA, Hendrix SL, et al. Cross-sectional geometry, bone strength, and bone mass in the proximal femur in black and white postmenopausal women. J Bone Miner Res. 2000;15:1992-1997.
90. Uusi-Rasi K, Semanick LM, Zanchetta JR, et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone. 2005;36:948-958.
91. Boivin G, Meunier PJ. Changes in bone remodeling rate influence the degree of mineralization of bone. Connect Tissue Res. 2002;43:535-537.
92. Boivin GY, Chavassieux PM, Santora AC, et al. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone. 2000;27:687-694.
93. Roschger P, Rinnerthaler S, Yates J, et al. Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone. 2001;29:185-191.
94. Eriksen EF, Melsen F, Sod E, et al. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone. 2002;31:620-625.
95. Ritman EL, Borah B, Dufresne TE, et al. 3-D synchrotron micro-CT allows unique insight of changes in bone quality with risedronate therapy [Abstract]. Calcif Tissue Int. 2003;74:383.
96. Schaffler MB. Role of bone turnover in microdamage. Osteoporos Int. 2003;14(suppl 5):73-80.
97. Mashiba T, Hirano T, Turner CH, et al. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res. 2000;15:613-620.
98. Diab T, Condon KW, Burr DB, et al. Age-related change in the damage morphology of human cortical bone and its role in bone fragility. Bone. 2005.
99. Boskey AL. Variations in bone mineral properties with age and disease. J Musculoskel Neuron Interact. 2002;2:532-534.
100. Currey JD. Role of collagen and other organics in the mechanical properties of bone. Osteoporos Int. 2003;14(suppl 5):S29-S36.
101. Burr D. The contribution of the organic matrix to the bone's material properties. Bone. 2002;31:8-11.
102. Paschalis EP, Shane E, Lyritis G, et al. Bone fragility and collagen cross-links. J Bone Miner Res. 2004;19:2000-2004.
103. Boskey AL. Bone mineral crystal size. Osteoporos Int. 2003;14(suppl 5):16-21.
104. Boskey AL. Variations in bone mineral properties with age and disease. J Musculoskelet Neuron Interact. 2002;2:532-534.
105. Cummings S, Black D, Pearson J, et al. How much of the reduction in risk of vertebral fractures by alendronate is explained by increased spine BMD? [Abstract]. J Bone Miner Res. 1999;14(suppl 1):S159.
106. Cummings SR, Black DM, Vogt TM, et al. Changes in BMD substantially underestimate the anti-fracture effects of alendronate and other antiresorptive drugs [Abstract 29]. J Bone Miner Res. 1996;11(suppl 1):S102.
107. Black DM, Sarkar S, Mitlak B, et al. What proportion of the effects of raloxifene (RLX) on vertebral fracture risk can be directly attributed to bone mineral density (BMD) effects? [Abstract no 1101]. J Bone Miner Res. 1999;14(suppl 1):S158.
108. Li Z, Meredith M, Hoseyni MS. A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med. 2001;20:3175-3188.